OPY Stock Recent News

NEW YORK , July 26, 2024 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.3 million or $0.99 basic earnings per share for the second quarter of 2024, compared with a net loss of $(9.4) million or $(0.85) basic earnings per share for the second quarter of 2023. Revenue for the second quarter of 2024 was $330.6 million, an increase of 8.0%, compared to revenue of $306.2 million for the second quarter of 2023.

Strategic Recruitment of 10 New Hires Builds on Oppenheimer's Momentum as the Credit Landscape and Macroeconomic Trends Signal Greater Demand for Leveraged Finance NEW YORK , July 15, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) —announced today the continued expansion of its Fixed Income Division with the addition of 10 more High Yield and Distressed Debt Team members. The additions coincide with a more challenging credit environment and expansion of the firm's restructuring and debt advisory capabilities.

Expanding the Depth and Breadth of Oppenheimer's Biotech Equity Research NEW YORK , July 11, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today the appointment of Andreas Argyrides as Executive Director and Senior Analyst covering the Biotechnology sector.  "We are thrilled to have Andreas join our biotech research team as we expand the depth and breadth of our industry expertise," said John Hellier, Senior Managing Director, Head of Equities for Oppenheimer.

Kumar Brings Extensive Financial Services Experience to Lead a Four-Person Team that Reflects Oppenheimer Research's Commitment to FinTech and Payments NEW YORK , July 9, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today the appointment of Rayna Kumar as Managing Director and Senior Analyst covering the Financial Technology sector. She will lead a four-person team from Oppenheimer's New York office.

Bhatia's Addition Exemplifies Continued Deployment of Resources  Towards Building a Leading Life Sciences Practice NEW YORK , June 24, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today that Kunal Bhatia joined as a Managing Director in the firm's Healthcare Investment Banking Group. He will be based in New York and report to Michael Margolis, R.Ph, Oppenheimer's Co-Head of Healthcare and Head of Healthcare Life Sciences Investment Banking.

TEL AVIV, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- via IBN –- HUB Cyber Security Ltd. (NASDAQ: HUBC), a developer of confidential computing cybersecurity solutions and advanced data services, today released the following statement regarding recent press reports about a settlement with Oppenheimer & Co.:

REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New York City.

WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at 11:45 AM ET on June 24, 2024 at the Oppenheimer Novel Targets in Immunology Summit in New York, NY.

MINNEAPOLIS--(BUSINESS WIRE)--Best Buy (NYSE: BBY) announces that Corie Barry, chief executive officer, and Matt Bilunas, chief financial officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on June 10, 2024, at 11:15 a.m. Eastern Time. A webcast of the event will be available at www.investors.bestbuy.com both live and after the event.

Highly experienced, London-based banker to lead firm's newly established Healthcare M&A practice NEW YORK , June 4, 2024 /PRNewswire/ -- Oppenheimer Europe (Oppenheimer) — a subsidiary of Oppenheimer Holdings, the leading investment bank and wealth manager (NYSE: OPY) — announced today a further expansion of its European investment banking footprint with the addition of Martin Chamberlin. Based in London, Chamberlin will serve as a Managing Director and Head of European Healthcare.